The strengths of the POSH study include the large cohort size, few missing data, and inclusion of patients with young-onset breast cancer, which led to a large number of BRCA1 and BRCA2 mutation carriers and a high number of events, ensuring that the study was well powered for the main outcome analysis. The gene discussed is BRCA2; the disease is breast carcinoma.